2026 Paul A. Beavis: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	46	18832	17269	555	532	242	13520

Overview

Paul A. Beavis is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research focuses primarily on immunology, oncology, and molecular biology, with extensive publications across these fields.

Key areas of study for Paul A. Beavis include:

Immunology and Microbiology
Medicine
Biochemistry, Genetics and Molecular Biology

Within subfields, their work spans:

Immunology
Oncology
Molecular Biology
Genetics
Electrical and Electronic Engineering

The main topics of their research cover a range of subjects, including:

CAR-T cell therapy research
Immune Cell Function and Interaction
Immunotherapy and Immune Responses
Cancer Immunotherapy and Biomarkers
CRISPR and Genetic Engineering
T-cell and B-cell Immunology
Viral Infectious Diseases and Gene Expression in Insects

Prominent recent publications reflect these research interests:

Targeting the epigenetic regulation of antitumour immunity, 2020, Nature Reviews Drug Discovery
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion, 2020, Cancer Research
Tissue-resident memory T cells in breast cancer control and immunotherapy responses, 2020, Nature Reviews Clinical Oncology
Sex-specific adipose tissue imprinting of regulatory T cells, 2020, Nature
Cellular networks controlling T cell persistence in adoptive cell therapy, 2021, Nature Reviews Immunology

Paul A. Beavis collaborates frequently with other researchers. Notable co-authors include:

Phillip K. Darcy
Imran G. House
Kevin Sek
Junyun Lai
Amanda X. Y. Chen

Their work is regularly published in several venues, with multiple contributions to:

Cancer Cell
Nature
Nature Communications
Cancer Research
Immunity

Best Publications

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

Peter Savas;Balaji Virassamy;Chengzhong Ye;Agus Salim;Agus Salim

1000
Citations
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Marian L Burr;Marian L Burr;Marian L Burr;Christina E Sparbier;Yih-Chih Chan;James C Williamson

930
Citations
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

Liza B John;Christel Devaud;Connie P M Duong;Carmen S M Yong

781
Citations
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.

Imran G House;Imran G House;Peter Savas;Peter Savas;Junyun Lai;Junyun Lai;Amanda X. Y. Chen;Amanda X. Y. Chen

697
Citations
RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

Sherene Loi;Sherene Loi;Sathana Dushyanthen;Paul A. Beavis;Roberto Salgado

653
Citations
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Sherene Loi;Sandra Pommey;Benjamin Haibe-Kains;Paul A Beavis

555
Citations
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Marian L. Burr;Marian L. Burr;Marian L. Burr;Christina E. Sparbier;Christina E. Sparbier;Kah Lok Chan;Kah Lok Chan;Yih-Chih Chan

475
Citations
CD73: a potent suppressor of antitumor immune responses

Paul. A. Beavis;John Stagg;Phillip K. Darcy;Phillip K. Darcy;Mark J. Smyth;Mark J. Smyth

420
Citations
Targeting the epigenetic regulation of antitumour immunity.

Simon J Hogg;Simon J Hogg;Simon J Hogg;Paul A Beavis;Paul A Beavis;Mark A Dawson;Mark A Dawson;Ricky W Johnstone;Ricky W Johnstone

410
Citations
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.

Florida Voli;Emanuele Valli;Luigi Lerra;Kathleen Kimpton

396
Citations
Tumor immune evasion arises through loss of TNF sensitivity

Conor J. Kearney;Conor J. Kearney;Stephin J. Vervoort;Stephin J. Vervoort;Simon J. Hogg;Simon J. Hogg;Kelly M. Ramsbottom

382
Citations
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

Paul A. Beavis;Upulie Divisekera;Upulie Divisekera;Christophe Paget;Christophe Paget;Melvyn T. Chow;Melvyn T. Chow

374
Citations
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

A J Davenport;R S Cross;R S Cross;K A Watson;Y Liao

347
Citations
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Paul A. Beavis;Paul A. Beavis;Nicole Milenkovski;Nicole Milenkovski;Melissa A. Henderson;Melissa A. Henderson;Liza B. John;Liza B. John

316
Citations
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

Paul A. Beavis;Paul A. Beavis;Melissa A. Henderson;Melissa A. Henderson;Lauren Giuffrida;Lauren Giuffrida;Jane K. Mills;Jane K. Mills

314
Citations
Tissue-resident memory T cells in breast cancer control and immunotherapy responses

Ann Byrne;Peter Savas;Peter Savas;Sneha Sant;Sneha Sant;Ran Li;Ran Li

305
Citations
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Simon J. Hogg;Stephin J. Vervoort;Sumit Deswal;Christopher J. Ott

280
Citations
Immunosuppressive activities of adenosine in cancer.

Bertrand Allard;Paul A Beavis;Phillip K Darcy;John Stagg

259
Citations
Relevance of tumor-infiltrating lymphocytes in breast cancer

Sathana Dushyanthen;Paul A. Beavis;Peter Savas;Zhi Ling Teo

248
Citations
CD73-deficient mice are resistant to carcinogenesis.

John Stagg;Paul A. Beavis;Upulie Divisekera;Mira C.P. Liu

224
Citations